Add to ORKGA rare disease is a health disorder that affects a small proportion (i.e., <1:2,000 in Europe) of the population. There are more than 7000 distinct rare diseases affecting 350-400 million people worldwide. The low prevalence of rare diseases makes the drug development economically unattractive. However, the introduction of regulatory and legal incentives has encouraged the pharmaceutical industry and led to the introduction of a number of orphan therapies, which are in general very costly. Notwithstanding of incentives, only 4% of rare diseases have specific therapies and many rare diseases still lack treatment. The access of many orphan drugs is constrained, especially in low- and middle-income countries, due to several challenges that are...
WHO defines rare disease as a disease or condition with a prevalence of ≤1/1000 population. Other de...
More than 10 years have been passed since the European Parliament approved a law to encourage pharma...
This work is about how healthcare issues can be reframed from a sustainable and inclusive developmen...
Rare diseases have a prevalence of lower than 5 in 10,000 inhabitants and are life-threatening or ch...
Estimates of the frequencies of rare disorders vary from country to country; the global average defi...
A rare disease, or orphan disease, in the United States is a condition with a national prevalence of...
Rare diseases are recognized as non-prevalent health disorders. Availability, accessibility, and aff...
Rare diseases, although individually rare, affect approximately 6–8% of the total population with mo...
ABSTRACT Rare diseases are a major public health problem and public health challenge. Orphan drugs ...
This project carries out an analysis of market access of orphan drugs for rare diseases. In the Euro...
p. 343-350An orphan disease is a disease with a very low prevalence. Although there are 5000-7000 or...
An estimated 400 million individuals suffer from rare diseases globally. Tackling rare diseases has ...
While orphan drug regulations have proven to be an effective tool in stimulating the development of ...
While orphan drug regulations have proven to be an effective tool in stimulating the development of ...
Rare diseases are a heterogenic group of disorders with a little in common except of their rarity af...
WHO defines rare disease as a disease or condition with a prevalence of ≤1/1000 population. Other de...
More than 10 years have been passed since the European Parliament approved a law to encourage pharma...
This work is about how healthcare issues can be reframed from a sustainable and inclusive developmen...
Rare diseases have a prevalence of lower than 5 in 10,000 inhabitants and are life-threatening or ch...
Estimates of the frequencies of rare disorders vary from country to country; the global average defi...
A rare disease, or orphan disease, in the United States is a condition with a national prevalence of...
Rare diseases are recognized as non-prevalent health disorders. Availability, accessibility, and aff...
Rare diseases, although individually rare, affect approximately 6–8% of the total population with mo...
ABSTRACT Rare diseases are a major public health problem and public health challenge. Orphan drugs ...
This project carries out an analysis of market access of orphan drugs for rare diseases. In the Euro...
p. 343-350An orphan disease is a disease with a very low prevalence. Although there are 5000-7000 or...
An estimated 400 million individuals suffer from rare diseases globally. Tackling rare diseases has ...
While orphan drug regulations have proven to be an effective tool in stimulating the development of ...
While orphan drug regulations have proven to be an effective tool in stimulating the development of ...
Rare diseases are a heterogenic group of disorders with a little in common except of their rarity af...
WHO defines rare disease as a disease or condition with a prevalence of ≤1/1000 population. Other de...
More than 10 years have been passed since the European Parliament approved a law to encourage pharma...
This work is about how healthcare issues can be reframed from a sustainable and inclusive developmen...